Pacylex Pharmaceuticals Announces Publication in Current Oncology of First Clinical Experience with an N-myristoyltransferase (NMT) inhibitor in a Patient with Diffuse Large B-cell Lymphoma (DLBCL)

Pacylex Pharmaceuticals Announces the Initiation of a Phase 1 Clinical of PCLX-001 in Non-Hodgkin’s Lymphomas and Solid Tumor Patients. First clinical patient dosed at Cross Cancer Institute, Edmonton.

Pacylex will present updates on the journey of PCLX-001 to the Clinic at the Annual BIO Meeting and the summer FASEB conference on protein lipidation.

Pacylex Pharmaceuticals and Greenfire Bio announced the closing of Series A financing for Pacylex. These funds will be used to support the initial Phase 1 clinical investigation of PCLX-001 in multiple cancers.